As per the current market research conducted by the CMI Team, the global Cancer Immunotherapy Market size is expected to record a CAGR of 7.2% from 2024 to 2033. In 2024, the market size is projected to reach a valuation of USD 168.1 Billion. By 2033, the valuation is anticipated to reach USD 314.4 Billion.
Cancer Immunotherapy Market: Growth Factors and Dynamics
- Increasing Prevalence of Cancer: The rising incidence of various types of cancer globally is a significant growth factor for the cancer immunotherapy market. As the prevalence of cancer continues to increase, there is a growing need for effective and targeted treatment options, driving the demand for immunotherapies.
- Advancements in Research and Technology: Ongoing research and technological advancements in the field of cancer immunotherapy have led to the development of novel and more efficient therapies. Breakthroughs in understanding the immune system’s role in cancer defense have resulted in the discovery of new targets and treatment modalities, fostering the market growth.
- Efficacy and Reduced Side Effects: Immunotherapies often offer improved efficacy compared to traditional cancer treatments, and they are known for causing fewer severe side effects. This has increased patient acceptance and contributed to the growing adoption of immunotherapies as a preferred option in cancer treatment regimens.
- Rise in Investment and Funding: The cancer immunotherapy market has witnessed increased investments and funding from both the public and private sectors. Pharmaceutical companies, biotechnology firms, and research institutions are heavily investing in the development of innovative immunotherapies, driving the market’s growth.
- Expanding Approvals and Indications: Regulatory agencies around the world are granting approvals for new immunotherapeutic drugs and expanding their indications. This has broadened the scope of immunotherapy applications across different cancer types, providing healthcare providers with more options for personalized and targeted treatment strategies.
- Patient Awareness and Demand: Growing awareness among patients regarding the benefits of immunotherapy, coupled with increased access to information through various channels, has led to a higher demand for these treatments. Patients and healthcare professionals are increasingly recognizing the potential of immunotherapy in improving outcomes and survival rates, contributing to market dynamics.
- Collaborations and Partnerships: The cancer immunotherapy market has witnessed a surge in collaborations and partnerships between pharmaceutical companies, biotech firms, and academic institutions. These alliances facilitate the pooling of resources, expertise, and technologies, accelerating the development and commercialization of innovative immunotherapies.
Cancer Immunotherapy Market: Partnership and Acquisitions
- In 2023, AstraZeneca obtained European Union approval for the tablet formulation of Calquence (acalabrutinib) to treat Chronic Lymphocytic Leukaemia (CLL) in adults. This regulatory approval strengthens AstraZeneca’s market position, expanding treatment options and supporting revenue growth in the field of CLL therapy for adult patients.
- In 2023, The FDA approved Merck’s anti-PD-1 therapy, KEYTRUDA, for neoadjuvant and adjuvant treatment in patients with resectable non-small cell lung cancer (NSCLC). This signifies KEYTRUDA’s role in enhancing surgical outcomes by addressing NSCLC at different stages, providing an advanced treatment option for eligible patients undergoing surgery.
- In 2022, The FDA approved Takeda’s FRUZAQLA (fruquintinib) for the treatment of Previously Treated Metastatic Colorectal Cancer. This marks a significant milestone, offering an additional therapeutic option for patients with advanced colorectal cancer who have undergone prior treatments.
Report Scope
| Feature of the Report | Details |
| Market Size in 2024 | USD 168.1 Billion |
| Projected Market Size in 2033 | USD 314.4 Billion |
| Market Size in 2023 | USD 156.8 Billion |
| CAGR Growth Rate | 7.2% CAGR |
| Base Year | 2023 |
| Forecast Period | 2024-2033 |
| Key Segment | By Type of Immunotherapy, Cancer Type, Mode of Administration, End-Users and Region |
| Report Coverage | Revenue Estimation and Forecast, Company Profile, Competitive Landscape, Growth Factors and Recent Trends |
| Regional Scope | North America, Europe, Asia Pacific, Middle East & Africa, and South & Central America |
| Buying Options | Request tailored purchasing options to fulfil your requirements for research. |
Cancer Immunotherapy Market: COVID-19 Analysis
The COVID-19 pandemic has had a significant impact on the Cancer Immunotherapy Market, with the industry experiencing both positive and negative effects. Here are some of the key impacts:
- Treatment Disruptions and Delayed Initiations: The COVID-19 pandemic led to disruptions in healthcare services, including cancer diagnosis and treatment. Many cancer patients experienced delays in immunotherapy initiation or interruptions in their treatment schedules due to lockdowns, resource reallocation, and concerns about virus exposure in healthcare settings.
- Supply Chain Disruptions and Clinical Trials Challenges: The pandemic disrupted global supply chains, affecting the availability of drugs and components needed for cancer immunotherapy. Clinical trials for new immunotherapies faced challenges, with delays in patient recruitment, monitoring, and data collection, impacting the overall research and development timeline.
- Resumption of Regular Healthcare Services: As healthcare systems adapted to the pandemic, there has been a gradual resumption of regular services, including cancer screenings, diagnosis, and treatment. This has allowed cancer immunotherapy treatments to regain momentum.
- Emphasis on Telemedicine and Remote Monitoring: The adoption of telemedicine and remote monitoring tools increased during the pandemic, providing healthcare professionals with alternative means to monitor and support cancer patients. This has facilitated continued patient care while minimizing in-person visits, ensuring the safety of both patients and healthcare providers.
- Accelerated Regulatory Approvals: Regulatory agencies have implemented measures to expedite the review and approval of essential medications, including cancer immunotherapies. Fast-track designations and emergency use authorizations have helped bring new therapies to market more quickly, addressing treatment gaps.
- Increased Investment in Research and Development: The recognition of the importance of immunotherapy in cancer treatment has led to increased investment in research and development. Pharmaceutical companies and research institutions are intensifying efforts to innovate and bring new immunotherapies to market, driven by the lessons learned from the pandemic.
In conclusion, the COVID-19 pandemic has had a mixed impact on the Cancer Immunotherapy Market, with some challenges and opportunities arising from the pandemic.
List of the prominent players in the Cancer Immunotherapy Market:
- Roche Holding AG
- Merck & Co. Inc.
- Bristol Myers Squibb Company
- AstraZeneca plc
- Johnson & Johnson
- Novartis International AG
- Pfizer Inc.
- Amgen Inc.
- Eli Lilly and Company
- Gilead Sciences Inc.
- Sanofi
- Regeneron Pharmaceuticals Inc.
- Seattle Genetics Inc.
- Genentech Inc.
- Celgene Corporation
- Others
The Cancer Immunotherapy Market is segmented as follows:
By Type of Immunotherapy
- Monoclonal Antibodies (mAbs)
- Checkpoint Inhibitors
- Cancer Vaccines
- Adoptive Cell Transfer (ACT)
- Cytokine Therapy
By Cancer Type
- Lung Cancer
- Breast Cancer
- Colorectal Cancer
- Melanoma
- Prostate Cancer
- Leukemia/Lymphoma
- Others
By Mode of Administration
- Oral
- Intravenous (IV)
- Subcutaneous
- Intramuscular
- Others
By End-Users
- Hospitals
- Cancer Research Institutes
- Clinics
- Ambulatory Surgical Centers (ASCs)
- Others
Regional Coverage:
North America
- U.S.
- Canada
- Mexico
- Rest of North America
Europe
- Germany
- France
- U.K.
- Russia
- Italy
- Spain
- Netherlands
- Rest of Europe
Asia Pacific
- China
- Japan
- India
- New Zealand
- Australia
- South Korea
- Taiwan
- Rest of Asia Pacific
The Middle East & Africa
- Saudi Arabia
- UAE
- Egypt
- Kuwait
- South Africa
- Rest of the Middle East & Africa
Latin America
- Brazil
- Argentina
- Rest of Latin America